Archives of Dermatological Research最新文献

{"title":"Fast view on the first resistant dermatophyte to terbinafine, Trichophyton rubrum","authors":"Ali Abdul Hussein S. AL-Janabi","doi":"10.1007/s00403-025-04220-z","DOIUrl":"10.1007/s00403-025-04220-z","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of Simvastatin in the treatment of vitiligo: a systematic review and meta-analysis of randomized controlled trials","authors":"Song Zhang,&nbsp;Ibrahim Serag,&nbsp;Shereen Mohamed Olama,&nbsp;Mahmoud G. A. Saleh,&nbsp;E. A. Shaban,&nbsp;Mostafa Hossam El Din Moawad","doi":"10.1007/s00403-025-04234-7","DOIUrl":"10.1007/s00403-025-04234-7","url":null,"abstract":"<div><p>Vitiligo is an autoimmune skin disorder characterized by progressive depigmentation due to melanocyte destruction. Despite various treatment options, achieving complete repigmentation remains challenging. Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has demonstrated anti-inflammatory and immunomodulatory effects, making it a promising candidate for vitiligo treatment. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of Simvastatin in vitiligo treatment. A systematic search of PubMed, Scopus, Web of Science, and Cochrane Library was conducted following PRISMA guidelines. Only RCTs comparing Simvastatin with a control or pre-post Simvastatin assessments in vitiligo patients were included. Six RCTs with a total of 371 patients met the eligibility criteria. The primary outcomes analyzed were VASI reduction and excellent repigmentation response (≥ 75% repigmentation). Secondary outcomes included changes in total cholesterol, triglycerides, and low-density lipoprotein (LDL) levels. Meta-analyses were performed using a random-effects model, and heterogeneity was assessed using the I² statistic. Simvastatin significantly reduced VASI scores (SMD = −0.30; 95% CI −0.52–−0.07, p = 0.010; I² = 0%). The likelihood of achieving excellent repigmentation (≥ 75%) was significantly higher in the Simvastatin group (OR = 6.54; 95% CI 1.08–38.42, p = 0.04; I² = 0%). Additionally, Simvastatin led to a significant reduction in total cholesterol (−62.1 mg/dL; 95% CI −74.0–−50.2, p &lt; 0.00001; I² = 0%), triglycerides (−65.08 mg/dL; 95% CI −89.81–−40.35, p &lt; 0.00001; I² = 69%), and LDL (−66.13 mg/dL; 95% CI −77.50–−54.76, p &lt; 0.00001; I² = 90%). Simvastatin demonstrates significant efficacy in vitiligo treatment, improving VASI scores and repigmentation while also lowering lipid levels. This is the first meta-analysis on this topic, providing evidence for Simvastatin as a potential adjunct therapy. Further large-scale RCTs are needed to validate these findings.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of current dermatopathology training across U.S. residency programs","authors":"Evelyn F. Fagan,&nbsp;Joseph T. McGrath,&nbsp;Divya Sharma,&nbsp;Sierra Thomas,&nbsp;Corey Georgesen,&nbsp;Erin X. Wei","doi":"10.1007/s00403-025-04185-z","DOIUrl":"10.1007/s00403-025-04185-z","url":null,"abstract":"<div><p>Dermatopathology (DP) is integral to dermatology residency training, aiding in accurate diagnoses and clinical interpretations. This study evaluates the current state of DP education and faculty backgrounds in dermatology residency programs, using information available on 142 ACGME-accredited dermatology residency programs. The focus was on DP training, including dedicated rotations, training years, and duration as well as DP faculty and fellowship opportunities. Of the programs analyzed, 53.52% offered distinct DP rotations. Residents in these programs spent an average of 11.37 weeks in DP training, with 70.83% providing DP exposure in the first year. The average number of board-certified dermatopathologists per program was 2.91 (SD = 2.11); however, 23.19% of programs lacked dermatology-trained dermatopathologists. DP fellowships were available in 36.62% of programs and among fellowship directors, 63.46% were board-certified in anatomic pathology and 51.98% in dermatology. While DP training is widely offered, the extent and structure of this training vary across residency programs with many lacking dedicated rotations or first-year exposure. Both dermatology-trained and pathology-trained dermatopathologists contribute to academic settings, although fellowship directors are more commonly trained in pathology. This highlights the need for greater consistency and clarity in DP training across residency programs to ensure comprehensive exposure in this essential field.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying key targets and immune environment in wound healing based on iron overload-related genes","authors":"Yinbo Peng,&nbsp;Juxiang Sheng,&nbsp;Tiantian Liu,&nbsp;Ruizhe He,&nbsp;Peng Xu","doi":"10.1007/s00403-025-04140-y","DOIUrl":"10.1007/s00403-025-04140-y","url":null,"abstract":"<div><p>Wound healing (WH) poses a significant socio-economic burden due to its high incidence and recurrence rates. Iron overload (IO) could be a factor leading to delayed WH. This study thus analyzed IO-related genes (IORGs) in WH, offering possibilities for developing new therapeutic strategies. Differential gene expression (DEGs) analysis was conducted between the WH group and intact skin (IS) group, intersected with IORGs to obtain differentially expressed IORGs (DE-IORGs). Functional enrichment analysis and potential drug screening were performed on DE-IORGs. A protein–protein interaction (PPI) network of DE-IORGs was constructed, and hub genes were identified using CytoHubba and MCODE methods. ROC curves of hub genes were plotted, and their expression levels in WH and IS groups as well as inter-gene correlations were analyzed. Additionally, immune infiltration variances in WH and IS groups, along with miRNA and TFs of hub genes, were examined. Finally, the effect of EGFR on skin wound healing was verified by scratch healing assay. 39 DE-IORGs were predominantly enriched in signaling pathways like HIF-1 signaling pathway and Th17 cell differentiation. Potential drugs for treating WH (e.g., felbamate, SA-94315, GANT-58, rucaparib) were identified. Three hub genes related to IO in WH were pinpointed (HIF1A, CDKN2A, EGFR) with diagnostic value. Immune infiltration analysis showed higher levels of immune cells like endothelial cells and macrophages in the WH group. Additionally, 55 miRNAs (e.g., hsa-mir-200a-3p, hsa-mir-218-5p) and 2 TFs (L3MBTL2, ZNF76) regulating the three hub genes were predicted. Cell experiments showed that EGFR could promote skin wound healing. The study suggested HIF1A, CDKN2A, and EGFR as potential diagnostic biomarkers for effective WH diagnosis, offering new insights into identifying potenti1al therapeutic targets for WH treatment.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enduring outcomes of minimally ınvasive approaches for facial rejuvenation","authors":"Elif Sari,&nbsp;Aynur Aliyeva","doi":"10.1007/s00403-025-04238-3","DOIUrl":"10.1007/s00403-025-04238-3","url":null,"abstract":"<div><p>Facial rejuvenation procedures have gained popularity as individuals seek nonsurgical methods to address signs of aging. These procedures encompass a range of minimally invasive techniques, including botulinum toxin applications, dermal fillers, PRP, and thread lifting. This study aimed to assess patient satisfaction and evaluate the short- and long-term outcomes of these minimal invasive facial rejuvenation procedures. Patients aged 18–65 who underwent facial rejuvenation at an Ear, Nose, and Throat Clinic were included. Procedures had botulinum toxin applications, dermal fillers, PRP, and PDO threads. Follow-up evaluations were conducted at 4–6 months for botulinum toxin and PRP and one year for other procedures. Visual analog scales and self-satisfaction measured beauty perception data after treatments. Botulinum toxin applications effectively reduced dynamic wrinkles, while dermal fillers provided volumetric support with varying longevity. PRP improved skin tone, brightness, moisture, and fine wrinkles. Patient satisfaction levels varied across procedures. Minimal invasive facial rejuvenation procedures offer a nonsurgical approach to address aging-related concerns. Botulinum toxin, dermal fillers, PRP, and PDO threads provide unique benefits, but their outcomes and satisfaction levels differ among patients. Understanding these variations is crucial for informed decision-making in facial rejuvenation.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143845807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency of sleep disturbances and signs of attention deficit and hyperactivity disorder in schoolchildren with atopic dermatitis","authors":"Priscila Vernizi Roth,&nbsp;Marcela Fisher de Almeida,&nbsp;Enzo Paolo Brandão Gouveia,&nbsp;Renata Drizlionoks,&nbsp;Rafaela Cachiolo Antunes,&nbsp;Mariana Aparecida Pasa Morgan,&nbsp;Ana Chrystina Souza Crippa,&nbsp;Vânia Oliveira Carvalho","doi":"10.1007/s00403-025-04235-6","DOIUrl":"10.1007/s00403-025-04235-6","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Assessment of miR-19b-3p, miR-182-5p, and miR-155-5p expression and its relationship with alopecia areata severity","authors":"Ahmed Ibrahim AbdElneam,&nbsp;Mohammed Saleh Al-Dhubaibi,&nbsp;Saleh Salem Bahaj,&nbsp;Ghada Farouk Mohammed,&nbsp;Lina Mohammed Atef","doi":"10.1007/s00403-025-04240-9","DOIUrl":"10.1007/s00403-025-04240-9","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143845808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ligilactobacillus salivarius Lac45 inhibits MRSA and suppresses inflammation in human keratinocyte","authors":"Punploy Klawkla,&nbsp;Hung Gia Tran,&nbsp;Poorichaya Somparn,&nbsp;Somying Tumwasorn,&nbsp;Tanittha Chatsuwan,&nbsp;Jongkonnee Wongpiyabovorn","doi":"10.1007/s00403-025-04227-6","DOIUrl":"10.1007/s00403-025-04227-6","url":null,"abstract":"<div><p>Dysbiosis, an imbalance in skin microflora, is a key contributor to inflammatory skin conditions, including atopic dermatitis (AD), seborrheic dermatitis (SD), and psoriasis. In AD, <i>Staphylococcus aureus</i> colonization of skin lesions is prevalent approximately 70% of cases, with disease severity positively correlating with bacterial presence. Moreover, methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) is found in 10–30% of AD skin lesions, highlighting the need for novel therapeutic strategies that target both microbial imbalance and inflammation. This study evaluates <i>Ligilactobacillus salivarius</i> Lac45 (LS-Lac45), a breast milk-derived bacterial strain, for its antimicrobial and anti-inflammatory potential in dermatology. We assessed its antimicrobial activity against MRSA using an agar disk-diffusion assay and its anti-inflammatory effects in a peptidoglycan (PGN)-induced inflammation model in HaCaT keratinocytes. To elucidate its mechanisms of action, mass spectrometry was used to analyze protein expression changes in LS-Lac45-treated keratinocytes. Our results demonstrate that live LS-Lac45 effectively inhibits MRSA growth. Additionally, heat-killed LS-Lac45 significantly reduces PGN-induced production of pro-inflammatory cytokines IL-6, IL-8, and TNF-α. Proteomic analysis further identifies LS-Lac45-mediated modulation of immune-related proteins, including heat shock protein 60, metallothionein 2A, and antioxidant-1, suggesting a role in inflammatory regulation. These findings highlight LS-Lac45 as a candidate for managing MRSA-associated inflammatory skin conditions, particularly AD. While this study provides key insights into its antimicrobial and immunomodulatory properties, further research is needed to evaluate its probiotic characteristics and clinical applicability in dermatology.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143840516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous epidermal growth factor receptor expression (EGFR) and soluble EGFR levels are elevated in patients with pemphigus vulgaris: a longitudinal study","authors":"Kanmani Indra Couppoussamy,&nbsp;Medha Rajappa,&nbsp;Laxmisha Chandrashekar","doi":"10.1007/s00403-025-04207-w","DOIUrl":"10.1007/s00403-025-04207-w","url":null,"abstract":"<div><p>Epidermal Growth Factor Receptor (EGFR) signalling is thought to be involved in the pathogenesis of pemphigus vulgaris. The objective was to assess the cutaneous EGFR mRNA expression and serum soluble EGFR (sEGFR) levels among Pemphigus patients in comparison to the healthy controls. This was a cross-sectional study with a longitudinal follow up. Thirty patients with pemphigus vulgaris and 30 controls were recruited. We measured cutaneous EGFR mRNA expression and sEGFR serum levels in pemphigus vulgaris patients at baseline, at three- and six-months following treatment. There was a significant (<i>p</i> = 0.007) difference of the EGFR mRNA fold expression between cases (3.07 (IQR (Interquartile range) 0.76 to 13.20)) at baseline as compared to the controls (1.005 (Interquartile range (IQR) 0.63 to 2.30)). The median sEGFR levels were significantly (<i>p</i> &lt; 0.0001) higher in the cases (4.33 ng/ml (IQR 3.01 ng/ml to 9.33 ng/ml)) compared to controls (1.52 ng/ml (IQR 0.79 ng/ml to 2.75 ng/ml)) at the baseline. There was a significant positive correlations of EGFR mRNA expression (<i>r</i> = 0.47) and sEGFR levels (<i>r</i> = 0.46) with pemphigus disease activity. The limitation of the study was smaller sample size. EGFR gene expression and sEGFR levels are significantly increased in pemphigus vulgaris. They significantly correlate with disease activity and decrease with treatment.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143845726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life, sleep, and psychological well-being in chronic spontaneous urticaria patients receiving omalizumab: a case–control study","authors":"Mustafa Esen,&nbsp;Abdullah Demirbaş,&nbsp;Esin Diremsizoglu","doi":"10.1007/s00403-025-04231-w","DOIUrl":"10.1007/s00403-025-04231-w","url":null,"abstract":"<div><p>Chronic spontaneous urticaria (CSU) impacts both physical and mental well-being, causing distress and sleep disturbances. While omalizumab reduces disease activity, its effects on mental health and quality of life remain unclear. This study assesses the psychosocial burden and sleep disturbances in CSU patients receiving omalizumab compared to healthy controls and explores their relationship with disease parameters. This case––control study included 210 CSU patients receiving omalizumab for at least three months and 210 age- and sex-matched healthy controls. Disease severity was assessed using the Urticaria Activity Score over 7 Days (UAS7) and Urticaria Control Test (UCT), while quality of life was evaluated with the Chronic Urticaria Quality of Life Questionnaire (CU-Q₂oL). Psychological distress and sleep disturbances were measured using validated scales, including the Perceived Stress Scale (PSS), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS). CSU patients had significantly higher scores for perceived stress, depression, anxiety, and daytime sleepiness compared to controls (p &lt; 0.001). Patients with a good response to omalizumab also showed significantly higher psychological distress and poorer sleep quality than controls (p &lt; 0.001). Omalizumab response was good in 29.5%, moderate in 38.6%, and limited in 31.9% of patients. Despite treatment, 32.9% reported no change in quality of life, while 35.7% had mild and 31.4% had moderate improvement. A history of atopic disease was present in 55.7% of patients, who had significantly higher daytime sleepiness scores than those without (p = 0.045). In CSU patients, while omalizumab improves symptoms and quality of life, psychological distress persists in substantial subsets, highlighting the need to address mental health and lifestyle factors.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00403-025-04231-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143845727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}